PFEB.F PFIZER INC.CDR REG.S
- Market cap
- EUR 135B
- P/E
- 40.3x
- P/B
- 1.70x
- ROE
- 8.5%
- Dividend yield
- 5.97%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PFEB.F undervalued?
Graham numberPFEB.F trades 74.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PFIZER INC.CDR REG.S fundamental analysis
No fundamental analysis for PFIZER INC.CDR REG.S yet.
PFIZER INC.CDR REG.S stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PFIZER INC.CDR REG.S
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, …
Full company profilePFIZER INC.CDR REG.S financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
PFIZER INC.CDR REG.S annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 81.3B | 101B | 59.6B | 63.6B | 62.6B | 61.4B |
| Gross Profit | 50.5B | 66.8B | 34.6B | 45.8B | 46.5B | 45.9B |
| Operating Income | 20.2B | 38.1B | 4.42B | 14.9B | 17.4B | 17.2B |
| EBITDA | - | 41.0B | 9.56B | 18.1B | 16.8B | 16.9B |
| Net Income | 22.0B | 31.4B | 2.12B | 8.03B | 7.77B | 7.57B |
| EPS | 3.91 | 5.59 | 0.38 | 1.42 | 1.37 | 1.33 |
| Balance Sheet | ||||||
| Total Assets | 181B | 197B | 227B | 213B | 208B | 205B |
| Total Liabilities | 104B | 101B | 137B | 125B | 121B | 115B |
| Shareholders' Equity | 77.2B | 95.7B | 89.0B | 88.2B | 86.5B | 89.0B |
| Cash & Short-term Investments | 1.94B | 416M | 2.85B | 1.04B | 1.14B | 1.82B |
| Cash Flow | ||||||
| Operating Cash Flow | 32.6B | 29.3B | 8.70B | 12.7B | 11.7B | 11.8B |
| Capital Expenditure | 2.71B | 3.24B | 3.91B | 2.91B | 2.63B | 2.06B |
| Free Cash Flow | 29.9B | 26.0B | 4.79B | 9.84B | 9.08B | 9.71B |
| Ratios | ||||||
| ROE | 28.5% | 32.8% | 2.4% | 9.1% | 9.0% | 8.5% |
| ROA | 12.1% | 15.9% | 0.9% | 3.8% | 3.7% | 3.7% |
| Net Profit Margin | 27.0% | 31.0% | 3.6% | 12.6% | 12.4% | 12.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
PFIZER INC.CDR REG.S dividends
- Dividend yield
- 5.97%
- Forward dividend
- 0.48 EUR
- Payout ratio
- 125.7%
- Ex-dividend date
- Nov 6, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 9.77B | 1.72 | 125.7% |
| 2024 | USD 9.51B | 1.68 | 118.4% |
| 2023 | USD 9.25B | 1.64 | 436.4% |
| 2022 | USD 8.98B | 1.60 | 28.6% |
| 2021 | USD 8.73B | 1.55 | 39.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns PFIZER INC.CDR REG.S
Ownership data of PFIZER INC.CDR REG.S is not available yet.
PFIZER INC.CDR REG.S company profile
- Company name
- PFIZER INC.CDR REG.S
- Ticker
- PFEB.F
- ISIN
- CA7170651060
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 75,000
- Fiscal year end
- December
- Address
- 66 Hudson Boulevard East, New York, NY, United States, 10001-2192
- Phone
- 212 733 2323
- Website
- pfizer.com
About PFIZER INC.CDR REG.S
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
PFIZER INC.CDR REG.S management
10- Dr. Albert Bourla D.V.M., Ph.D.Chairman of the Board & CEO · born 1962
- Dr. Chris Boshoff FMedSci, M.D., Ph.D.Chief Scientific Officer and President of Research & Development · born 1964
- Mr. Douglas M. LanklerExecutive VP & Chief Legal Officer · born 1966
- Mr. Aamir MalikExecutive VP & Chief U.S. Commercial Officer · born 1976
- Ms. Cecile GueganExecutive VP & CFO · born 1971
- Ms. Jennifer B. DamicoSenior VP, Controller & Principal Accounting Officer · born 1969
- Mr. Dennis P. HancockExecutive VP & Chief Information Officer
- Ms. Francesca M. DeMartinoChief Investor Relations Officer
- Ms. Payal Sahni BecherChief People Experience Officer & Executive VP · born 1975
- Dr. Michael S. Vincent M.D., Ph.D.Senior VP and Chief Scientific Officer of Inflammation & Immunology